||WO||WO/2013/055219 - UREA FINISHING METHOD||18.04.2013||
||PCT/NL2012/050715||STAMICARBON B.V.||MENNEN, Johannes Henricus|
Disclosed is a method for urea finishing. A urea solution is subjected to crystallization and, other than in conventional processes, the urea crystals are shaped by exerting mechanical force onto them. Thus, the conventional prilling or granulation finishing steps can be avoided, and so are the corresponding emissions of ammonia and/or dust. The crystallization comprises a flash crystallization. The invention also pertains to the urea particles obtainable by the process, to a urea plant, and to a method of modifying an existing urea plant.
||WO||WO/2013/050882 - EQUIPMENT FOR STRUCTURIZATION AND POLARIZATION OF FUEL, COMBUSTION MIXTURE OR WATER||11.04.2013||
||PCT/IB2012/002851||KUREGYAN, Kamo||KUREGYAN, Kamo|
The invention relates to engine construction, to equipment for improving fuel and combustion mixture. Also may be used for water processing. Economy of fuel and decrease of noxious air emissions in the atmosphere are achieved. Equipment for structurization and polarization of fuel, combustion mixture or water, comprises a body in a form of a hollow cylinder with a smooth inside surface and a rod mounted in the body, both made of current-conducting materials and connectable to the electric circuit. The equipment is supplied with a battery of current-conducting discs interleaved with insulating ones, positioned on the rod. The size of a working gap for passing fuel between the tops of the discs and the body doesn't exceed 1/10 of the size of the working surface of the body. The body and the rod are made of duralumin alloy, but the current-conducting discs of aluminum. The plain surfaces of the current-conducting discs are performed with electro insulating cover, without covering the tops of the discs.
||WO||WO/2013/040478 - HYR1-DERIVED COMPOSITIONS AND METHODS OF TREATMENT USING SAME||21.03.2013||
||PCT/US2012/055604||LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER||IBRAHIM, Ashraf, S.|
The disclosure features isolated polypeptides of Hyr1. The disclosure further features vaccines and antibodies useful in treating or preventing candidiasis or Acinetobacter infections or both. Further disclosed are isolated polypeptides consisting of between 14 and 20 amino acids for vaccine preparation. The specific amino acid sequences of isolated polypeptides of Hyr1 are also disclosed.
||WO||WO/2013/033656 - METHODS FOR THE TREATMENT OF BREAST CANCER||07.03.2013||
||PCT/US2012/053551||SYNDAX PHARMACEUTICALS, INC.||GOODENOW, Robert|
Described herein are methods for the treatment of breast cancer in a subject. In particular, methods are provided for the treatment of resistant, metastatic breast cancer with a combination of entinostat and an aromatase inhibitor.
||WO||WO/2013/020600 - PHARMACEUTICAL COMPOSITION COMPRISING A DRUG CONTAINING AT LEAST ONE TOXICOPHORE FUNCTION AND N-ACETYL-L-CYSTEINE||14.02.2013||
||PCT/EP2011/063829||CROSS SA||ASSANDRI, Alessandro|
The present invention relates to a pharmaceutical composition containing at least one drug containing at least a toxicophore function, N-acetyl-L-cysteine (NAC), at least one antioxidant agent and at least one pharmaceutically acceptable excipient, and the same for use in the prevention and/or reduction of the occurrence of idiosyncratic adverse drug reactions ( IADRs ) caused by said drug.
||WO||WO/2013/017650 - FORMULATIONS COMPRISING SACCHAROMYCES BOULARDII AND SUPEROXIDE DISMUTASE FOR CONTROLLING OBESITY||07.02.2013||
||PCT/EP2012/065119||GNOSIS SPA||CASTAGLIUOLO, Ignazio|
Disclosed is a composition containing Saccharomyces cerevisiae var boulardii and the enzyme superoxide dismutase.
||WO||WO/2013/015831 - METHODS AND COMPOSITIONS FOR VACCINATING AGAINST STAPHYLOCOCCUS AUREUS||31.01.2013||
||PCT/US2012/000328||NOVADIGM THERAPEUTICS, INC.||YEAMAN, Michael, R.|
The invention features a method of vaccinating a mammal against Staphylococcus aureus which includes the steps of: a) identifying a mammal at risk for the development of a Staphylococcus aureus skin or soft tissue infection; and b) administering to said mammal an immunogenic amount of a vaccine that includes a polypeptide including an isolated agglutinin-like sequence (Als) 3 protein (Als3p), or an immunogenic fragment thereof, in a pharmaceutically acceptable medium.
||WO||WO/2013/014567 - INDAZOLES||31.01.2013||
||PCT/IB2012/053546||PFIZER LIMITED||COE, Jotham, Wadsworth|
The present invention relates to compounds of formula (I) to pharmaceutically acceptable salts therefore and to pharmaceutically acceptable solvates of said compounds and salts, wherein the substituents are defined herein; to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly asthma and COPD.
||WO||WO/2013/011137 - PRODUCTION AND USE OF BACTERIAL HISTAMINE||24.01.2013||
||PCT/EP2012/064351||VERSALOVIC, James||VERSALOVIC, James|
A method is provided of selecting specific probiotic lactic acid bacteria producing histamine and the use of such strains for beneficial effects for mammals. In particular the present invention relates to a method of selecting a lactic acid bacterial strain for use in the local production of histamine in a mammal, wherein said method comprises screening bacteria for the presence of an active histidine operon and selecting a strain which has an active histidine operon and is capable of producing histamine. Preferably said strain is selected for its ability to produce histamine at a level of greater than 250 pg/ml. The present invention further provides products comprising the strains obtainable by the selection methods of the invention for use in the local production of histamine in a mammal, in particular for use in the treatment or prophylaxis of inflammatory conditions.
||WO||WO/2013/008217 - 4 - PIPERIDINYL COMPOUNDS FOR USE AS TANKYRASE INHIBITORS||17.01.2013||
||PCT/IB2012/053613||NOVARTIS AG||CHEN, Christine Hiu-Tung|
The present invention provides for compounds of formula (I).The present invention also provides for pharmaceutical compositions and combinations comprising a compound of formula (I) as well as for the use of such compounds as tankyrase inhibitors and in the treatment of Wnt signaling and tankyrase 1 and 2 signaling related disorders which include, but are not limited to, cancer.